Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Abbott Laboratories had a difficult last three years, with its stock price trading sideways as sales driven by COVID-19 plummeted.
Abbott Laboratories (NYSE:ABT) Shares Acquired by Harvest Portfolios Group Inc.
Abbott Laboratories stock opened at $106.22 on Tuesday.
Additionally, the ruling itself would only apply to the FDA and Danco Laboratories, one of the manufacturers of the abortion pill.
America First Investment Advisors LLC’s holdings in Abbott Laboratories were worth $16,756,000 at the end of the most recent quarter.
Amundi raised its holdings in shares of Bio-Rad Laboratories by 45.0% during the fourth quarter.
Analysts expect that IDEXX Laboratories, Inc. will post 9.6 EPS for the current fiscal year.
An illustrative cross-section of Alteryx's customer base: Netflix (), Abbott Laboratories (), Marriott Hotels () are all among Alteryx's anchor clients, spanning every industry.
Apple has discussed developing VR content for the platform with about half a dozen media partners, including Walt Disney Co. and Dolby Laboratories Inc.
Source: https://mybroadband.co.za/news/gadgets/477423-how-apples-reality-pro-headset-will-work.html
Ardevora Asset Management LLP grew its position in Bio-Rad Laboratories by 9.5% during the fourth quarter.
Arizona State Retirement System’s holdings in IDEXX Laboratories were worth $11,308,000 at the end of the most recent quarter.
As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 9.57 EPS for the current year.
Asset Management One Co. Ltd. lifted its stake in Silicon Laboratories by 9.1% in the 2nd quarter.
Atlas Capital Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $44,000.
Atlas Capital Advisors LLC purchased a new position in Bio-Rad Laboratories in the second quarter valued at about $50,000.
Barclays increased their price target on shares of Abbott Laboratories from $127.00 to $132.00 and gave the company an “overweight” rating in a research note on Monday, July 24th.
Barrington Research lowered shares of Dolby Laboratories from an “outperform” rating to a “market perform” rating in a report on Friday, November 18th.
Bio-Rad Laboratories, Inc. has a 1 year low of $344.63 and a 1 year high of $572.70.
BlackRock Inc. raised its position in Dolby Laboratories by 1.6% in the second quarter.
BTIG Research boosted their price objective on shares of Abbott Laboratories from $125.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, April 17th.